Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,500 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $21.82, for a total value of $272,750.00. Following the transaction, the chief executive officer directly owned 890,392 shares of the company’s stock, valued at $19,428,353.44. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Friday, October 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.33, for a total value of $266,625.00.
• On Friday, September 26th, Samuel Kintz sold 3,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.06, for a total value of $74,222.00.
• On Tuesday, September 23rd, Samuel Kintz sold 2,800 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.03, for a total value of $56,084.00.
• On Friday, September 19th, Samuel Kintz sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.25, for a total transaction of $20,250.00.
• On Wednesday, September 17th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.09, for a total transaction of $95,450.00.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $21.27 on Friday. The stock has a market cap of $1.26 billion, a P/E ratio of -11.56 and a beta of 0.80. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $26.09. The company has a fifty day moving average price of $20.41 and a 200 day moving average price of $20.14.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $41.20.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Quantbot Technologies LP bought a new stake in shares of Enliven Therapeutics in the 1st quarter valued at approximately $60,000. BNP Paribas Financial Markets boosted its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares in the last quarter. AlphaQuest LLC bought a new stake in Enliven Therapeutics in the third quarter valued at $96,000. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 194.3% during the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after acquiring an additional 3,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS raised its stake in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after acquiring an additional 2,500 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.